JP2018004657A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018004657A5 JP2018004657A5 JP2017175482A JP2017175482A JP2018004657A5 JP 2018004657 A5 JP2018004657 A5 JP 2018004657A5 JP 2017175482 A JP2017175482 A JP 2017175482A JP 2017175482 A JP2017175482 A JP 2017175482A JP 2018004657 A5 JP2018004657 A5 JP 2018004657A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- concentration
- avp
- copeptin
- elevated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100017238 AVP Human genes 0.000 claims 5
- 101700084127 AVP Proteins 0.000 claims 5
- 239000002464 receptor antagonist Substances 0.000 claims 4
- 210000004369 Blood Anatomy 0.000 claims 2
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229960003957 Dexamethasone Drugs 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 206010002869 Anxiety symptom Diseases 0.000 claims 1
- 102400000739 Corticotropin Human genes 0.000 claims 1
- 101800000414 Corticotropin Proteins 0.000 claims 1
- 206010054089 Depressive symptom Diseases 0.000 claims 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims 1
- 229960000258 corticotropin Drugs 0.000 claims 1
- 230000004797 therapeutic response Effects 0.000 claims 1
Claims (6)
- うつ症状および不安症状の少なくとも一方を有する患者におけるＶ１Ｂ受容体アンタゴニストに対する治療応答を予測する方法であって、前記患者の血液試料中のコペプチン濃度を測定し、または前記患者の脳脊髄液の試料中のＡＶＰ濃度を測定し、あるいはこれら両方を測定し、
健常個体におけるコペプチンおよびＡＶＰ濃度の少なくとも一方と比較して上昇したコペプチンおよび上昇したＡＶＰ濃度の少なくとも一方が、Ｖ１Ｂ受容体アンタゴニストによる治療に対して応答する患者を示す方法。 - デキサメタゾンにより前記患者を前治療し、続いて前記血液試料中の前記コペプチン濃度および脳脊髄液の前記試料中の前記ＡＶＰ濃度の少なくとも一方を測定するステップをさらに含む、請求項１に記載の方法。
- 前記患者を少なくとも１つの併用デキサメタゾン／コルチコトロピン試験（ｄｅｘ／ＣＲＨ試験）に供することをさらに含む、請求項２に記載の方法。
- 前記ｄｅｘ／ＣＲＨ試験は、前記患者が高ＨＰＡ系調節異常を有することを示す、請求項３に記載の方法。
- Ｖ１Ｂ受容体アンタゴニストによる治療に対して応答する患者を示す前記上昇したコペプチン濃度が、５ｐｍｏｌ／Ｌ以上、場合により５〜７ｐｍｏｌ／Ｌの範囲である、請求項１〜４のいずれか一項に記載の方法。
- Ｖ１Ｂ受容体アンタゴニストによる治療に対して応答する患者を示す前記上昇したＡＶＰ濃度が、４ｐｇ／ｍｌ以上のＡＶＰ、場合により４〜６ｐｇ／ｍｌのＡＶＰである、請求項１〜５のいずれか一項に記載の方法。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1210686.0 | 2012-06-15 | ||
| GBGB1210686.0A GB201210686D0 (en) | 2012-06-15 | 2012-06-15 | V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015516647A Division JP6309511B2 (ja) | 2012-06-15 | 2013-06-17 | 上昇したａｖｐレベルおよび上昇したコペプチンレベルの少なくとも一方を有する患者の治療における使用のためのｖ１ｂ受容体アンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018004657A JP2018004657A (ja) | 2018-01-11 |
| JP2018004657A5 true JP2018004657A5 (ja) | 2018-04-12 |
| JP6608891B2 JP6608891B2 (ja) | 2019-11-20 |
Family
ID=46641019
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015516647A Active JP6309511B2 (ja) | 2012-06-15 | 2013-06-17 | 上昇したａｖｐレベルおよび上昇したコペプチンレベルの少なくとも一方を有する患者の治療における使用のためのｖ１ｂ受容体アンタゴニスト |
| JP2017175482A Active JP6608891B2 (ja) | 2012-06-15 | 2017-09-13 | うつ症状および不安症状の少なくとも一方を有する患者におけるｖ１ｂ受容体アンタゴニストに対する治療応答を予測する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015516647A Active JP6309511B2 (ja) | 2012-06-15 | 2013-06-17 | 上昇したａｖｐレベルおよび上昇したコペプチンレベルの少なくとも一方を有する患者の治療における使用のためのｖ１ｂ受容体アンタゴニスト |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20150150846A1 (ja) |
| EP (2) | EP3276010B1 (ja) |
| JP (2) | JP6309511B2 (ja) |
| ES (1) | ES2873926T3 (ja) |
| GB (1) | GB201210686D0 (ja) |
| WO (1) | WO2013186399A1 (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201210686D0 (en) | 2012-06-15 | 2012-08-01 | Holsboermaschmeyer Neurochemie Gmbh | V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level |
| GB201310782D0 (en) * | 2013-06-17 | 2013-07-31 | Max Planck Innovation Gmbh | Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms |
| WO2019099615A1 (en) * | 2017-11-17 | 2019-05-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of copeptin to modulate the immune response and hematopoiesis, and stimulate bone growth |
| KR102318236B1 (ko) * | 2020-02-18 | 2021-10-26 | 한림대학교 산학협력단 | 혈중 코펩틴의 농도를 이용한 지연성 뇌허혈 진단 방법 |
| KR20230090589A (ko) * | 2021-12-15 | 2023-06-22 | 국립해양생물자원관 | 성게 유래 펩타이드 및 이의 용도 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2895961B2 (ja) | 1992-12-17 | 1999-05-31 | フアイザー・インコーポレイテツド | Ｃｒｆアンタゴニストとしてのピロロピリミジン |
| EP0723533A1 (en) | 1993-10-12 | 1996-07-31 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
| TW574214B (en) | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
| US5591588A (en) * | 1994-09-20 | 1997-01-07 | Gideon Goldstein | Method for the diagnosis of depression based on monitoring blood levels of arginine vasopressin and/or thymopoietin |
| US6403599B1 (en) | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
| US7067664B1 (en) | 1995-06-06 | 2006-06-27 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| TR199800792T2 (xx) | 1996-02-07 | 1998-07-21 | Janssen Pharmaceutica N.V. | CRF resept�r antagonistleri olarak pirazolopirimidinler. |
| US6060478A (en) | 1996-07-24 | 2000-05-09 | Dupont Pharmaceuticals | Azolo triazines and pyrimidines |
| EA006626B1 (ru) | 1996-07-24 | 2006-02-24 | Дюпон Фармасьютикалз Компани | Азолопиримидины, фармацевтическая композиция и способ лечения |
| FR2796380B3 (fr) | 1999-07-15 | 2001-08-17 | Sanofi Synthelabo | Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant |
| US20030092019A1 (en) | 2001-01-09 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia |
| SK287603B6 (sk) | 2001-03-13 | 2011-03-04 | Bristol-Myers Squibb Pharma Company | 4-(2-Butylamino)-2,7-dimetyl-8-(2-metyl-6-metoxypyrid-3- yl)pyrazol-[1,5-a]-1,3,5-triazín, farmaceutická kompozícia obsahujúca túto zlúčeninu, použitie tejto zlúčeniny v terapii a na prípravu farmaceutickej kompozície a výrobok obsahujúci túto zlúčeninu |
| CA2498509A1 (en) * | 2002-05-17 | 2003-11-27 | Riken | Method of detecting gene polymorphism |
| GR1004664B (en) | 2002-11-26 | 2004-09-02 | Bionature E A Ltd | The charakteristics and advantages of our invention are illustrated by the following description, methods and results of our research, attached figures and supporting references |
| GB0308208D0 (en) | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
| US7528124B2 (en) | 2003-08-28 | 2009-05-05 | Taisho Pharmaceutical Co., Ltd. | 1,3-dihydro-2H-indol-2-one derivative |
| US20050069936A1 (en) | 2003-09-26 | 2005-03-31 | Cornelius Diamond | Diagnostic markers of depression treatment and methods of use thereof |
| JP2008509674A (ja) * | 2004-08-13 | 2008-04-03 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | うつ病および不安についての処置応答を決定および予測するための組成物および方法 |
| EP1628136A1 (en) | 2004-08-19 | 2006-02-22 | B.R.A.H.M.S. Aktiengesellschaft | Method of diagnosis of disease using copeptin |
| GB0519957D0 (en) | 2005-09-30 | 2005-11-09 | Sb Pharmco Inc | Chemical compound |
| WO2006072458A2 (de) | 2004-12-31 | 2006-07-13 | Abbott Gmbh & Co. Kg | Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung |
| WO2006080574A1 (ja) | 2005-01-28 | 2006-08-03 | Taisho Pharmaceutical Co., Ltd. | １，３－ジヒドロ－２ｈ－インドール－２－オン化合物、及び芳香族複素環が縮合したピロリジン－２－オン化合物 |
| JP2009538331A (ja) | 2006-05-22 | 2009-11-05 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | 抑うつ障害のための治療 |
| UY30846A1 (es) * | 2006-12-30 | 2008-07-31 | Abbott Gmbh & Amp | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos |
| PL2520670T3 (pl) * | 2007-06-12 | 2014-07-31 | Max Planck Gesellschaft | Nowe polimorfizmy w abcb1 związane z brakiem odpowiedzi klinicznej na leki |
| WO2009113985A1 (en) | 2008-03-13 | 2009-09-17 | Maria Athanasiou | Genetic markers associated with response to antidepressants |
| WO2009130232A1 (en) | 2008-04-24 | 2009-10-29 | Glaxo Group Limited | Pyrazolo [1, 5 -a] pyrazine derivatives as antagonists of v1b receptors |
| US9644240B2 (en) | 2009-10-22 | 2017-05-09 | Leiden University | Disease susceptibility |
| US20150278438A1 (en) | 2012-04-23 | 2015-10-01 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Genetic predictors of response to treatment with crhr1 antagonists |
| JP2015516979A (ja) | 2012-04-23 | 2015-06-18 | ホルスボールマッシュマイヤー ニューロケミー ゲーエムベーハーＨｏｌｓｂｏｅｒｍａｓｃｈｍｅｙｅｒ Ｎｅｕｒｏｃｈｅｍｉｅ Ｇｍｂｈ | Ｃｒｈ過剰活性を有する患者の治療に用いるためのｃｒｈｒ１アンタゴニスト |
| GB201210686D0 (en) | 2012-06-15 | 2012-08-01 | Holsboermaschmeyer Neurochemie Gmbh | V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level |
| GB201310782D0 (en) | 2013-06-17 | 2013-07-31 | Max Planck Innovation Gmbh | Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms |
-
2012
- 2012-06-15 GB GBGB1210686.0A patent/GB201210686D0/en not_active Ceased
-
2013
- 2013-06-17 EP EP17168747.8A patent/EP3276010B1/en active Active
- 2013-06-17 ES ES17168747T patent/ES2873926T3/es active Active
- 2013-06-17 US US14/407,594 patent/US20150150846A1/en not_active Abandoned
- 2013-06-17 JP JP2015516647A patent/JP6309511B2/ja active Active
- 2013-06-17 EP EP13729363.5A patent/EP2861253A1/en not_active Withdrawn
- 2013-06-17 WO PCT/EP2013/062552 patent/WO2013186399A1/en active Application Filing
-
2017
- 2017-09-13 JP JP2017175482A patent/JP6608891B2/ja active Active
- 2017-10-26 US US15/794,520 patent/US20180042898A1/en not_active Abandoned
-
2019
- 2019-08-15 US US16/541,622 patent/US10857129B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018004657A5 (ja) | ||
| Nissen et al. | Soluble CD163 changes indicate monocyte association with cognitive deficits in Parkinson's disease | |
| WO2016046640A3 (en) | Methods for predicting drug responsiveness | |
| WO2014201516A3 (en) | Biomarker identification | |
| WO2015006489A8 (en) | Blood-based screen for detecting neurological diseases in primary care settings | |
| EP4234583A3 (en) | Evaluation and treatment of bradykinin-mediated disorders | |
| MX2017010569A (es) | Dispositivo, plataforma y ensayo para evaluacion de celulas. | |
| JP2017505897A5 (ja) | ||
| WO2017025617A8 (en) | Method for the quantification of faecalibacterium prausnitzii phylogroup i and/or phylogroup ii members and the use thereof as biomarkers | |
| Richards et al. | Biomarkers and asthma management: analysis and potential applications | |
| Kim et al. | Usefulness of impulse oscillometry and fractional exhaled nitric oxide in children with Eosinophilic bronchitis | |
| GB2528657A8 (en) | Sample analysing device | |
| Seltenhammer et al. | Micromorphological changes in cardiac tissue of drug‐related deaths with emphasis on chronic illicit opioid abuse | |
| WO2015049390A3 (en) | Kidney disease biomarker | |
| JP2017508144A5 (ja) | ||
| JP2011528797A5 (ja) | ||
| Ross et al. | Older men display elevated levels of senescence‐associated exercise‐responsive CD 28null angiogenic T cells compared with younger men | |
| Balbão et al. | Evaluation of adrenal function in critically ill children | |
| WO2017167942A8 (en) | Method for predicting the response of melanoma patients to a medicament | |
| JP2020056595A5 (ja) | ||
| JP5695075B2 (ja) | アルツハイマー病又は軽度認知症のバイオマーカー | |
| WO2018026969A3 (en) | Plazomicin antibodies and methods of use | |
| JP2016119915A5 (ja) | ||
| JP2015503106A5 (ja) | ||
| PL407244A1 (pl) | Bioczujnik elektrochemiczny do wykrywania białka S100B |